Answers are grounded in this paper and cite their sources.
Povorcitinib is an oral selective Janus kinase 1 inhibitor investigated for moderate-to-severe hidradenitis suppurativa (HS). The objective of this study was to synthesize response onset, depth, placebo-controlled efficacy, treatment outcomes through week 54, certainty of evidence, and safety. Searches of PubMed, CENTRAL, Embase.com, ClinicalTrials.gov, and WHO ICTRP conducted on November 9-10, 2026, yielded 158 source records; 58 duplicate entries were removed, leaving 100 distinct record groups. Three primary publications described five adult trials (1,481 participants), with additional linked reports and registrations. Study-level week-12 Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) risk differences were pooled separately for the 45-mg and 75-mg Phase III doses. Exploratory fixed-effect pooling of unadjusted responder counts estimated an absolute HiSCR50 benefit of 12.1 percentage points (95% confidence interval (CI) 5.6-18.6) with 45 mg and 12.3 points (95% CI 5.8-18.8) with 75 mg versus placebo. GRADE (Grading of Recommendations Assessment, Development and Evaluation) certainty for HiSCR50 was moderate for both doses. An existing Phase II trial yielded descriptive post hoc draining-tunnel subgroup outcomes without additional participants. Through week 54, HiSCR50 under post hoc modified nonresponder imputation ranged from 48.6% to 60.3%, versus 57.3%-71.4% in observed cases; no continuing placebo comparison was available. The two Phase III trials support week-12 efficacy versus placebo. Comparative dose superiority, post-crossover durability of advantage, and uncommon delayed adverse effects remain uncertain.
No takes yet. Share an insight, caveat, or question.
Alphonse et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: